- Home
- TECX vs QURE Comparison
TECX vs QURE Comparison
Compare TECX & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TECX
- QURE
- Stock Information
- Founded
- TECX 2019
- QURE 1998
- Country
- TECX United States
- QURE Netherlands
- Employees
- TECX N/A
- QURE N/A
- Industry
- TECX
- QURE Biotechnology: Pharmaceutical Preparations
- Sector
- TECX
- QURE Health Care
- Exchange
- TECX Nasdaq
- QURE Nasdaq
- Market Cap
- TECX 746.6M
- QURE 691.2M
- IPO Year
- TECX 2018
- QURE 2007
- Fundamental
- Price
- TECX $29.54
- QURE $12.84
- Analyst Decision
- TECX Strong Buy
- QURE Strong Buy
- Analyst Count
- TECX 5
- QURE 8
- Target Price
- TECX $80.50
- QURE $39.43
- AVG Volume (30 Days)
- TECX 661.7K
- QURE 820.4K
- Earning Date
- TECX 03-04-2025
- QURE 03-03-2025
- Dividend Yield
- TECX N/A
- QURE N/A
- EPS Growth
- TECX N/A
- QURE N/A
- EPS
- TECX N/A
- QURE N/A
- Revenue
- TECX N/A
- QURE $28,587,000.00
- Revenue This Year
- TECX N/A
- QURE $153.92
- Revenue Next Year
- TECX N/A
- QURE N/A
- P/E Ratio
- TECX N/A
- QURE N/A
- Revenue Growth
- TECX N/A
- QURE N/A
- 52 Week Low
- TECX $1.40
- QURE $3.73
- 52 Week High
- TECX $61.07
- QURE $19.18
- Technical
- Relative Strength Index (RSI)
- TECX 38.91
- QURE 38.20
- Support Level
- TECX $30.42
- QURE $12.72
- Resistance Level
- TECX $36.11
- QURE $14.42
- Average True Range (ATR)
- TECX 3.49
- QURE 0.85
- MACD
- TECX -0.94
- QURE -0.26
- Stochastic Oscillator
- TECX 0.81
- QURE 7.26
About TECX Tectonic Therapeutic Inc. Common Stock
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease.
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.